Pan-cancer adaptive immune resistance as defined by the Tumor Inflammation Signature (TIS): results from The Cancer Genome Atlas (TCGA)
10.1186/s40425-018-0367-1
June 22, 2018
Emerging Immunotherapeutic Agents
Edited by Micheal Kalos, Ignacio Melero, and Laszlo Radvanyi
This series is the culmination of a special call for papers that was conducted in early 2018. These original research articles add to the journal’s scope by addressing basic biophysical properties, synthesis and manufacturing, novel mechanisms of action, preclinical safety, pharmacokinetics (PK), pharmacodynamics (PD), immunogenicity, and regulatory information on new immunotherapy agents and their combinations. They focus on new agents that are intended to begin, or are undergoing, clinical development, while also including molecules that are in advanced clinical development or approved.
Immunomodulatory activities of pixatimod: emerging nonclinical and clinical data, and its potential utility in combination with PD-1 inhibitors
10.1186/s40425-018-0363-5
June 14, 2018
Targeting the TGFβ pathway with galunisertib, a TGFβRI small molecule inhibitor, promotes anti-tumor immunity leading to durable, complete responses, as monotherapy and in combination with checkpoint blockade
10.1186/s40425-018-0356-4
June 4, 2018
Adjuvant NY-ESO-1 vaccine immunotherapy in high-risk resected melanoma: a retrospective cohort analysis
10.1186/s40425-018-0345-7
May 18, 2018
Discovery and preclinical characterization of the antagonist anti-PD-L1 monoclonal antibody LY3300054
10.1186/s40425-018-0329-7
April 30, 2018